RRML - Is galectin-3 a promoter of ventricular dysfunction?
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Impact factor (2019): 0.945

Rejection rate (2020): 75%

Română English


Clarivate analytics (ISI) Impact factor


Advanced search


Top 10 downloaded articles
- June 2021 -
 
The evaluation of a diagnostic... 47
Prognostic value of serum lact... 20
The possibility of clinical us... 10
Romanian Review of Laboratory ... 9
Prevalence of ∆F508 cystic f... 9
Predictors associated with inc... 8
Essentials in the diagnosis of... 8
Platelets and Infections... 7
Evaluation of Plasma AA/DHA+EP... 7
Pseudohyponatremia and falsely... 7

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 26(1)/2018 DOI:10.2478/rrlm-2018-0001
XML
TXT

Review

Is galectin-3 a promoter of ventricular dysfunction?

Adrian Lupu, Silvia Lupu, Lucia Agoston-Coldea

Correspondence should be addressed to: Silvia Lupu

Abstract:

Heart failure is nowadays a common condition associated with high mortality and increased healthcare-related costs. Over the years, the research on heart failure management has been extensive in order to better diagnose and treat the condition. Since the progression of left ventricular dysfunction is a consequence of myocardial inflammation, apopotosis, and fibrosis leading to myocardium remodelling, several molecules that are involved in the inflammation pathways have been explored as possible biomarkers for the condition. The study of biomarkers and their key roles in inflammation could allow early identification of patients with heart failure, improve prognostic assessment, and provide a target for future therapies. Among currently studied biomarkers, extensive research has been conducted on galectin-3, a galactoside-binding lectin, which is synthetised and secreted when cardiomyocytes and fibroblasts are submitted to mechanical stress. Accordingly, it has been hypothesised that galectin-3 could be a promoter of left ventricular dysfunction. Galectin-3 has been shown to mediate inflammation by several different pathways which are further detailed in the current review. Also, we aimed to provide a comprehensive overview of existing evidence on the utility of galectin-3 in clinical settings associated with heart failure.

Keywords: Galectin-3, biomarker, heart failure, dyspnea, ventricular dysfunction, ventricular remodelling

Received: 10.9.2017
Accepted: 10.12.2017
Published: 15.12.2017

 
  PDF Download full text PDF
(820 KB)
     
 
How to cite
Lupu A, Lupu S, Agoston-Coldea L. Is galectin-3 a promoter of ventricular dysfunction?. Rev Romana Med Lab. 2018;26(1):21-36. DOI:10.2478/rrlm-2018-0001